三官能性抗体
↑ “The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial”. International Journal of Cancer 127 (9): 2209–21. (2010). doi:10.1002/ijc.25423. PMC 2958458. PMID 20473913. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2958458/.
↑ Kufer, P; Lutterbüse, R; Baeuerle, PA (2004). “A revival of bispecific antibodies”. Trends in Biotechnology 22 (5): 238–44. doi:10.1016/j.tibtech.2004.03.006. PMID 15109810.
↑ Lindhofer, H; Mocikat, R; Steipe, B; Thierfelder, S (1995). “Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies”. Journal of Immunology 155 (1): 219–25. PMID 7602098.